Compare VanEck Junior Gold Miners (GDXJ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Novartis AG — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 32.7× VanEck Junior Gold Miners's market cap, and Novartis AG pays a 3.31% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Novartis AG for 82 Days on average.
| GDXJ | NVS | |
|---|---|---|
Market Cap | $8.22B | $268.57B |
Volume | 3,212,198 | 1,532,573 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $168.62 |
52-Week Low | $87.56 | $121.80 |
Typical Hold Time | 41 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.43, up 4.85% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF is undergoing significant rebalancing, with multiple junior mining companies like Sinda Ltd. and Hemlo Mining Corp. being added to the fund as of September 2026, which may impact liquidity and composition. Key financial ratios are not applicable as this is an ETF tracking a basket of stocks.
The outlook is mixed; recent gold price strength above $4,400 (24/7 Wall Street, August 16, 2026) supports miner ETFs, but GDXJ's bearish technicals and institutional selling (Amundi reduced its stake by 50.5% as per Defense World, August 6, 2026) suggest caution. Risks include gold price volatility and the high-risk nature of junior miners. Investment appeal hinges on gold's momentum versus the ETF's technical weakness.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
